Autopsy report · NCT02928419
Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q
Cause of deathSlow enrollment
“"the study has been closed due to a low rate of patient enrollment (2 patients since the start of the trial)"”
Life of this trial
- Registered 1 year 5 months after it had already started.
- Ran for about 3 years 4 months before it stopped.
- 2 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Associazione Qol-one
- Sponsor type
- University, hospital or other
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Eltrombopag/Revolade; Placebo; Lenalidomide
- Participants
- 2
- Sites
- 50
- Countries
- France, Greece, Italy
Trials that died the same way
- Adipose Derived SVF for Aero-digestive & Enterocutaneous Fistulae
“Study closed due to lack of patient enrollment.” - Reiki for the Management of Neuropathic Pain
“Study closed due to substantial decrease in the desired patient population.” - Impact of Feeding on Pro-Inflammatory Cytokine Response in Neonates Receiving a RBC Transfusion
“Study is being closed due to insufficient patient population for enrollment.” - Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias
“Clinical trial was halted prematurely due to low enrollment” - Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer
“Closed to accrual to allow enrollment on another more promising trial.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.